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Abbreviations: CYP, cytochrome P450; dA, desoxyadenosine; DAPI, 4′,6-diamidino-2- 
phenylindole; dG, desoxyguansosine; DMEM, Dulbecco’s modified Eagle’s medium; DMSO,  
dimethyl sulfoxide; EDTA, ethylene diamine tetraacetate; ESI, FCS, fetal calf serum; gpt,   
xanthine-guanine phosphoribosyl transferase; HPLC, high performance liquid  
chromatography; LC, liquid chromatography; LOQ, limit of quantification;  MS, mass  
spectrometry; NMR nuclear magnetic resonance; PBS, phosphate-buffered saline; pRH,  
primary rat hepatocytes; RNAase, ribonuclease; RP 18, reversed phase C18; SDS, sodium  
dodecylsulfate; SP1, specificity protein 1;  SULT, sulfotransferase; TRIS,  
tris(hydroxymethyl) aminomethane; UDS, unscheduled DNA synthesis; UHPLC, ultra-high  


















Estragole is a natural constituent in herbs and spices and in products thereof such as essential 
oils or herbal teas. After cytochrome P450-catalyzed hydroxylation and subsequent sulfation, 
estragole acts as a genotoxic hepatocarcinogen forming DNA adducts in rodent liver. Because 
of the genotoxic mode of action and the widespread occurrence in food and phytomedicines a 
refined risk assessment for estragole is needed. We analyzed the time- and concentration-
dependent levels of the DNA adducts N2-(isoestragole-3‘-yl)-2‘-desoxyguanosine (E3’N2dG) 
and N6-(isoestragole-3‘-yl)-desoxyadenosine (E3’N6dA), reported to be the major adducts 
formed in rat liver, in rat hepatocytes (pRH) in primary culture after incubation with 
estragole. DNA adduct levels were measured via UHPLC-ESI-MS/MS using stable isotope 
dilution analysis. Both adducts were formed in pRH and could already be quantified after an 
incubation time of 1 h (E3’N6dA at 10 µM, E3’N2dG at 1µM estragole). E3’N2dG, the main 
adduct at all incubation times and concentrations, could be detected at estragole 
concentrations < 0.1 µM after 24 h and < 0.5 µM after 48h. Adduct levels were highest after 6 
h and showed a downward trend at later time-points, possibly due to DNA repair and/or 
apoptosis. While the concentration-response characteristics of adduct formation were 
apparently linear over the whole concentration range, strong indication for marked hypo-
linearity was obtained when the modeling was based on concentrations < 1 µM only. In the 
micronucleus assay no mutagenic potential of estragole was found in HepG2 cells whereas in 
HepG2-CYP1A2 cells 1 µM estragole led to a 3.2 fold and 300 µM to a 7.1 fold increase in 
micronuclei counts. Our findings suggest the existence of a ‘practical threshold’ dose for 
DNA adduct formation as an initiating key event of the carcinogenicity of estragole indicating 
that the default assumption of concentration-response-linearity is questionable, at least for the 





The allylic phenylpropanoid estragole is a natural constituent in herbs and spices such as anise 
basil, fennel, tarragon etc. (Atkinson, 2018). After oral exposure, estragole is readily absorbed 
from the gastrointestinal tract and can undergo metabolism mainly in the liver (Smith et al. 
2002). Among several metabolic pathways, there is a bioactivating pathway via 1’-
hydroxylation at the allylic side-chain with subsequent enzymatic sulfation. The semi-stable, 
reactive sulfate conjugate thus formed can undergo sulfate elimination under formation of 
covalent bonds of the remaining moiety to nucleophilic targets (Miller et al., 1983). The major 
enzymes catalyzing the first critical step (1’-hydroxylation) are cytochromes P450 (CYP), 
most notably CYP1A2 (Jeurissen et al., 2007), and for the phase II step (sulfation of 
1’hydroxyestragole), sulfotransferases, most notably SULT1A1 (Suzuki et al., 2012b).  
There is accumulating evidence that the 1’-sulfoxy metabolite of estragole can also react with 
DNA leading to covalent adducts with guanine or adenine (Phillips et al., 1981). These are 
considered as pro-mutagenic lesions and major contributors to the genotoxicity and 
carcinogenicity of estragole observed in laboratory rodents (Miller et al., 1983).  
In general, the family of allylic phenyl propanoides has been investigated by several authors 
for its capacity to form DNA adducts in the liver. Examples are methyleugenol (Herrmann et 
al., 2014), ß-asarone (Stegmüller et al., 2018) and estragole (Phillips et al., 1981). 
Genotoxicity research on estragole including the search for DNA adducts has been focused on 
the liver, the principal target organ of carcinogenicity in mice (Drinkwater et al., 1976) and 
probably also in rats (Suzuki et al., 2012a). DNA adduct structures reported or suggested by 
Phillips et al. (1981) to be formed in mouse liver in vivo upon treatment of the animals with  
1’hydroxyestragole are N2-(estragole-1′-yl)-2′-desoxyguanosine (E1′N2dG), the two 
diastereomeric adducts N2-(trans-isoestragole-3′-yl)-2′-desoxyguanosine (trans-iE3’N2dG) and 
N2-(cis-isoestragole-3′-yl)-2′-desoxyaguanosine (cis-iE3′N2dG) and the adenosine adduct (N6-
(isoestragole-3′-yl)-2′-desoxyadenosine (iE3′N6dA). In addition Wiseman et al. (1985) found 
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C8-(isoestragol-3'-yl)-2’- desoxyguanosine (C8iE3’dG) in a reaction of 1’-acetoxyestragole 
with desoxyguanosine. Using a similar approach, Punt et al. (2007) found the adducts 
C8iE3’dG, two diastereomers of E1′N2dG, and trans-iE3’N2dG, the latter being the major 
adduct found in incubations of 1’-hydroxyestragole with hepatic PAPS-fortified S9-mix from 
human, rat or mouse. In rats treated with estragole over four weeks, trans-iE3’N2dG trans-
iE3′N6-dA, and C8iE3’dG were found in the liver,  iE3’N2dG and iE3′N6-dA being the major 
adducts (Ishii et al., 2011). Suzuki et al. (2012b) found a dose-dependent increase in the same 
estragole-derived hepatic DNA adducts after treatment of mice with estragole. Furthermore, at 
a dose level of 250 mg/kg b.w., significant increases in hepatic mutations in the SP1- and the 
gpt-locus were found in females. In rats, estragole treatment also led to the formation of DNA 
adducts in the liver and increased mutation frequencies at the gpt-locus with doses of 200 and 
600 mg/kg b.w. At lower dose levels, no significant mutagenicity was found (Suzuki et al., 
2012a).  
Nesslany et al. (2010) found increased unscheduled DNA synthesis (UDS) in hepatocytes of 
male rats 12-16 h after treatment (by gavage) with estragole at 250 mg/kg b.w. and at higher 
doses. With tarragon leaves they could not see any effects (up to the maximum dose of 6.25 
g/kg b.w. (18.75 mg estragole/kg b.w.).  
Here, we present data on the levels of two major DNA adducts, reported to be formed in rat 
liver, in estragole-treated pRH with a special focus on concentration-response characteristics. 
Furthermore, we show results on micronuclei formation in human HepG2 hepatoma cells 
over-expressing human CYP1A2, an enzyme considered as the major contributor to the 1’-
hydroxylation of estragole as the initiating metabolic step leading to genotoxicity and 





2. Materials and methods 
2.1. Animals, cells and materials  
2’-Desoxyguanosine (dG), 2’-desoxyadenosine (dA), 2’-desoxycytosine were from 
AppliChem GmbH (Darmstadt, Germany) or TCI (Eschborn, Germany). The isotope-labeled 
nucleosides 15N5-dG and 15N5-dA with a degree of labeling of > 98 % were purchased from 
Silantes GmbH (Munich, Germany). Methanol (HPLC grade) was from VWR (Darmstadt, 
Germany), water was double distilled after deionization. RNAse was from Carl Roth 
(Karlsruhe, Germany), proteinase K and alkaline phosphatase from Sigma-Aldrich 
(Taufkirchen, Germany), phosphodiesterase and micrococcal nuclease from Worthington 
(Lakewood, NJ, USA). All other chemicals including solvents were at the highest purity 
commercially available from major suppliers. All plastic labware was from Greiner Bio-One 
(Frickenhausen, Germany).  
HepG2 cells were obtained from DSMZ (Heidelberg, Germany), HepG2 cells transfected with 
the human CYP1A2 gene (HepG2/CYP 1A2 cells, C7) were generated as described 
(Steinbrecht et al., 2020). pRH were isolated from young adult male Wistar rats, obtained 
from Janvier Labs (Le Genest-Saint-Isle, France). Animals were kept, and pRH were isolated 
according to the German Animal Protection Act and under the control of and with permission 
from the responsible authorities of the State of Rhineland-Palatinate, Germany. 
 
2.2. Synthesis and identification of estragole-derived DNA adducts 
N6-(isoestragole-3‘-yl)-desoxyadenosine (iE3’N6dA): 2′-Desoxyadenosine (100 mg; 371 
µmol) was diluted in 47.5 mL aqueous ammonium carbonate solution (10 mM). 1′-
acetoxyestragole (192 mg; 929 µmol) was diluted in 2.5 mL acetonitrile. Both solution were 
mixed. The reaction mixture was stirred for 72 h at 37 °C and subsequently separated via 
preparative HPLC. The solvent of the combined product containing fractions was removed via 
lyophilisation and the compounds were further dried in vacuo. Yield: 2 %. Analysis: tR 
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(HPLC) 24.8 min; tR (UHPLC) 3,71 min; LC-MS/MS fragmentation: [M+H]+ 398.2 m/z, [M-
desoxyribose]+ 282.8m/z, [M-dG]+ 147.1; 1H NMR (600 MHz, DMSO-d6) δ [ppm]: 2.25 (m, 
1 H, 2′dR); 2.72 (m, 1 H, 2′dR); 3.51 (m, 1 H, 3’R); 3.61 (m, 2 H, 3‘R); 3.69 (m, 1 H, 5′dR); 
3.72 (s, 3 H, OCH3); 3.86 (m, 1 H, 5′dR); 4.24 (s, 1 H, OH); 4.40 (s, 1 H, OH); 5.22 (s, 1 H, 
3′dR); 5.32 (m, 1 H, 4′dR); 6.21(m, 1 H, 1′dR); 6.34 (m, 1 H, 2′R); 6.45 (m, 1 H, 1′R); 6.85 
(m, 2 H, HAr); 7.32 (m, 2 H, HAr); 8.52 (m, 1 H, NH); 8.20 (s, 1 H, C2-dA); 8.35 (s, 1 H, 
C8-dA). 
N2-(isoestragole-3‘-yl)-2‘-desoxyguanosine (iE3’N2dG): 2′-Desoxyguanosine (100 mg; 351 
µmol) was diluted in 47.5 mL aqueous ammonium carbonate solution (10 mM). 1′-
acetoxyestragole (180 mg; 870 µmol) was diluted in 2.5 mL acetonitrile. Both solution was 
mixed. The reaction mixture was stirred for 72 h at 37 °C and subsequently separated via 
preparative HPLC. The solvent of the combined product containing fractions was removed via 
lyophilisation and the compounds were further dried in vacuo. Yield: 7.4 %. Analysis: tR 
(HPLC) 22.0 min; tR (UHPLC) 3,17 min; LC-MS/MS fragmentation: [M+H]+ 414.3 m/z, [M-
desoxyribose]+ 298.1 m/z, [M-dG]+ 147.1, [M-desoxyribose+NH3]+ 164,1; 1H NMR (600 
MHz, DMSO-d6) δ [ppm]: 2.12 (m, 1 H, 2′dR); 2.85 (m, 1 H, 2′dR); 3.48 (m, 1 H, 3’R); 3.55 
(m, 2 H, 3‘R); 3.72 (s, 3 H, OCH3); 3.73 (s, 1 H, 5’dR); 3.79 (s, 1 H, 5’dR); 4.35 (s, 1 H, 
OH); 4.88 (s, 1 H, OH);  5.28 (s, 1 H, 3′dR); 5.53 (m, 1 H, 4′dR); 6.10 (m, 1 H, 1′dR); 6.81 
(m, 1 H, 2′R); 6.90 (m, 1 H, 1′R); 6.87 (d, J= 8.44, 1 H, HAr); 6.90 (d, J= 8.44, 1 H, HAr); 
7.26 (d, J= 8.44, 1 H, HAr); 7.33 (d, J= 8,80, 1 H, HAr); 7.6 (s, 1 H, C8-dG); 8.52 (m, 1 H, 
NH). 
Isotope-labeled standards: 15N5-dG (1.121 mg; 4.12 μmol) or 15N5-dA (1.046 mg, 4.08 μmol) 
were used to synthesize isotope-labeled internal adduct standards with mg 7.98 and 7.98 mg 
1′-acetoxyestragole, respectively, in a total volume of 500 μl. Therefore 15N5-dG or 15N5-dA 
weighed directly into a 1.5 mL vial and solved in 440 µL aqueous ammonium carbonate 
solution (10 mM) and 1′-acetoxyestragole was solved in 60 µL acetonitrile. After vigorously 
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mixing of both solutions the reaction mixture was stirred over 72 h at 37 °C. Separation was 
accomplished by preparative HPLC. The solvent of the combined product containing fractions 
were reduced to in a speed vac. The concentration of the yielded isotope-labeled standard 
solutions was determined via HPLC-UV/VIS using known concentrations of the 
corresponding unlabeled derivatives. Yields: [15N5]-E3’N2dG: 1 %); [15N5]-(E3’N6dA) 13.1 
%. Analysis: LC-MS/MS: [15N5]-E3’N2dG: [M-H]+ 419.051 m/z [M-desoxyribose]+ 298.100 
m/z, [M-15N5dG]+ 147.000 m/z. [15N5]-E3’N6dA: [M-H]+ 403.227 m/z [M-desoxyribose]+ 
287.200 m/z, [M-15N5dA]+ 147.200 m/z. 
 
2.3. NMR spectroscopy 
NMR spectra were recorded using a Bruker (Bruker BioSpin, Rheinstetten, Germany) Avance 
600 MHz spectrometer at room temperature, the test compound being dissolved in DMSO-d6 
(1H NMR: δ 2.49 ppm). The data were processed using 1D Win NMR software (Bruker 
BinSpin, Rheinstetten, Germany).  
 
2.4. Preparative HPLC 
For separation an Agilent 1200 Series HPLC (Agilent Technologies, Kronberg, Germany) 
system equipped with two preparative pumps (G1361A), an automatic fraction collector 
(G1364B), and a Multi-Wavelength detector (MWD, MWD G1315A). As liquid phases 
double distilled water (A) and HPLC-grade methanol (B) or acetonitrile (C) were used. Data 
were analyzed using ChemStation software for LC (version B04.01, Agilent Technologies, 
Waldkirch, Germany). It was used an RP18 column (VDSpher PUR C18-SE, 5 μm, 250×20 
mm, VDS Optilab, Berlin, Germany). 
After injecting 10 ml sample volume, separation was carried out as follows (switch time/% 
B). For the first purification step of 15N5-E3’N2dG: 0 min/40%, 50 min/90%, 60 min/40% 
(flow rate 3 ml/min over 5 min, 15 ml/min over 55 min); for the second purification step of 
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15N5-E3’N2dG: 0 min/1%, 65 min/50%, 70 min/80%, 76 min/95%, 87 min/1% (15 ml/min 
throughout); for the separation of unlabeled E3’N2-dG: 0 min/40%, 50 min/90 %, 60 min/40% 
(3 ml/min over 5min, 15 ml/min over 55 min); for the purification of 15N5-E3’N6dA: 0 min/20 
%, 50 min/80 %, 60 min/20% (flow rate 2 ml/min over 5 min, 15 ml/min over 55 min); for the 
separation of unlabeled E3’N6dA: 0 min/20%, 50 min/80%, 60 min/20 % (3 ml/min over 5 
min, 15 ml/min over 55 min).   
 
2.5. Analytical HPLC 
The system consisted of an Agilent 1200 Series HPLC unit (Agilent Technologies, Kronberg, 
Germany), equipped with a G1322A degasser, a G1311A pump, a G1329A autosampler, a 
G1316A column oven, and a G1315A diode array detector. The system was run with a 
ChemStation for LC software (version B04.01, Agilent Technologies, Kronberg, Germany). 
As liquid phases 0.1 % aqueous formic acid (A), methanol (B) were used. After injection of a 
sample volume of 50 µl, the following gradients were used to monitor the reaction between 
dA/dG and 1’-acetoxyestragole or 3’-acetoxyanethol, respectively (switch time/% B): 0 min 
/1%, 20 min/70%, 25.1 min/95%, 30.1 min/1% (flow rate 1 ml/min at 25°C); for the 
separation of 15N5E3’N2-dG (switch time/% B): 0 min/1%, 20 min/50%, 21 min/80%, 29 
min/85%, 24.1 min/1% (flow rate 1 ml/min at 25°C). 
An RP18 column (LiChrospher®, 5 μm, 4.0 mm×4.0 mm, Merck, Darmstadt, Germany) with 
a pre-column filled with the same stationary phase was used.  
 
2.6. Quantification of DNA adducts (LC-MS/MS) 
Samples were separated on an Agilent 1290 Series UHPLC System (Agilent Technologies, 
Kronberg, Germany), equipped with a 6133A degasser, a G4220A pump, a G1367C 
autosampler, and a G1316C column oven. A UHPLC column filled with RP18 as stationary 
phase (U-VDSpher PUR C18-E 1.8 μm; 50×4.6 mm) and a pre-column filled with the same 
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material were used. As liquid phases 0.1% aqueous acetic acid (A) and methanol with 1 % 
acetic acid (B) were used at a flow rate of 0.8 ml/min at 25° C. Separation was achieved with 
a gradient with (switching time/% B) 0 min/10%, 1.2 min/50%, 4.3 min 90%, 4.31 min/95%, 
6.01 min/10 % at a flow rate of 0.8 ml/min. The injection volume was 5 μl. 
The system was coupled to a Sciex QTrap 5500 MS mass spectrometer AB Sciex, Darmstadt, 
Germany). Measurements were run using Analyst software 1.7 (AB Sciex, Darmstadt, 
Germany), and data analysis with Multiquant software 2.0  AB Sciex, Darmstadt, 
Germany).Ionization was achieved with an electron spray in the positive mode (ESI+) using 
Multiple Reaction Monitoring (MRM). Instrument specific parameters were the following: ion 
spray voltage 5.0 kV; ion source temperature 500 °C; curtain gas 45 psi; nebulizer gas 55 psi; 
heater gas 50 psi; dwell time 50 msec.  
 
2.7.Quantification of desoxyguanosine (dG) 
The dG concentrations in the hydrolysates were determined using HPLC/MS-MS 
methodology. The system consisted of an Agilent 1200 series equipped with 6133A degasser, 
a G1367C autosampler, a G1213B pump, and a G1316B column oven (Agilent, Waldkirch, 
Germany). Separation was carried out on a RP18 column (LiChrospher®, 5μm, 4.0mm x 125 
mm, Merck, Darmstadt, Germany) and a corresponding pre-column filled with the same 
stationary phase. As liquid phases 0.1% aqueous formic acid (A) and methanol (B) were used. 
Separation was achieved with a gradient with (switching time/ % B) 0 min/1%, 7 min/70%, 
12.1 min 95%, 17.1 min/1%, at a flow rate of 0.7 ml/min at 20°C. The injection volume was 
2.5 μl. 
The column was coupled to a TriplQuad mass spectrometer API3200 (AB Sciex, Darmstadt, 
Germany)) using Analyst Software 1.4.2 (Applied Biosystem, MDS Sciex, USA). For data 
analysis, the Multiquant Software 2.0 (AB Sciex, Darmstadt, Germany)) was used. Ionization 
was achieved with an electron spray in the positive mode (ESI+) using Multiple Reaction 
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Monitoring (MRM). Instrument specific parameters were the following: ion spray voltage 4.5 
kV; ion source temperature 450 °C; curtain gas 50 psi; nebulizer gas 45 psi; heater gas 50 psi; 
dwell time 100 msec.  
 
2.8. Cell culture 
Primary rat hepatocytes (pRH) were isolated in a two-step perfusion method (Schrenk et al., 
1992). Cell preparations with a vitality > 95 % were seeded on collagenated 100 mm Petri 
dishes for adduct analysis (7 x 106 cells/7 ml) or on 24 well plates for cytotoxicity 
measurement (2,5 x 105 cells/1 ml) in DMEM (low glucose, Life Technologies GmbH, 
Darmstadt, Germany) with 10% FCS (Life Technologies GmbH, Darmstadt, Germany) und 
1% Penicillin/Streptomycin-solution (Sigma-Aldrich, Taufkirchen, Germany). After 3-4 h, 
medium was replaced by fresh medium and the cells were incubated over 1 – 48 h with the 
test substances (dissolved in DMSO) or with 0.1 % DMSO only (negative control). 0.1 % 
saponin (final concentration, dissolved in water) was used as positive control for cytotoxicity 
testing. HepG2/CYP 1A2 (C7) cells were cultivated exactly as previously described (Steinbrecht et 
al., 2020). 
 
2.9. DNA extraction and hydrolysis, sample preparation  
After incubation, cells were washed with PBS and kept at -80°C until further processing. 
Therefore, the cells were lysed on ice with 800 µl lysis buffer (35 mM TRIS, 0.56 mM 
NaEDTA, 0.018 nM formic acid, 1 % SDS and 0.5 % TritonX100) and transferred into a 2 ml 
test tube. Then, 15 µl proteinase K (10 mg/ml) and 5 µl RNAse (10 mg/ml) were added and 
the mixture was kept for 3 - 4 h at 55 °C. After cooling to room temperature, 800 µl extraction 
solution I (phenol:chloroform:isoamyl alcohol, 25:24:1) were added and vortexed. The lysates 
were then centrifugated at 13,000 x g and 4°C for 10 min. The supernatants were incubated 
with 5 µl RNase (room temperature, 20 min), and were then treated with 700 µl extraction 
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solution II (chloroform:isoamyl alcohol, 24:1). After vortexing, the suspensions were 
centrifugated at 13,000 x g and 4°C for 10 min. The supernatants were removed and DNA 
was precipitated by adding 1.2 ml cold ethanol (100 %). After centrifugation at 13,000 x g 
and 4°C over 10 min, the pellets were dissolved in 250 µl water and 25 µl 3 M sodium acetate 
solution, and were DNA was precipitated with 500 µl isopropanol. After centrifugation at 
13,000 x g and 4°C over 10 min, the pellet was re-suspended in 700 µl aqueous ethanol (70 
%) and vortexed. After centrifugation (10 min at 4 °C and 13,000 x g), the pellet was dried at 
room temperature and dissolved in 50 µl water. The purity of the DNA was analyzed 
spectrophotometrically with a Nanodrop ND-1000 (ThermoScientific, Wilmington, NC, 
USA), and the DNA content was adjusted to 30 µg per sample. Each sample was spiked with 
50 fmol isotope-labeled adducts and 1 nmol 15N5-dG , an DNA was isolated according to 
Schumacher et al. (2013). 
 
2.10.Cytotoxicity testing 
pRH were seeded into collagenated 24 well plates (2,5 x 105 cells/ml) with 1 ml/well DMEM 
low glucose with 10% FCS and 1% penicillin/streptomycin solution over 3-4 h. HepG2 cells 
were seeded into 24 well plates (1.5 x 105 cells/ml) in 1 ml/well DMEM high glucose with 
sodium pyruvate, 10% FCS and 1% penicillin/streptomycin solution over 24 h, 
HepG2/CYP1A2 cells were cultured under the same conditions except for medium without 
added sodium pyruvate.  
Cultures were incubated over 24 h or 24 h and further cultivation for 72 h without test 
compound (HepG2 and HepG2/CYP1A2 cells) or 24 h (pRH) with the test substances 
dissolved in DMSO (0.1 % final concentration), DMSO only served as negative control, 0.1% 
saponin (final concentration) as positive control. After washing with PBS, 1 ml 44 µM 
resazurin solution in pure medium was added per well. After incubation over 60 min (HepG2 
and HepG2/CYP1A2 cells) or 90 min (pRH) with resazurin solution, fluorescence was 
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measured in a Fluoroscan plate reader at an excitation wavelength of 544 nm and an emission 
wavelength of 590 nm.  
 
2.11. Micronucleus assay 
HepG2 or HepG2/CYP1A2 cells were seeded on 60 mm Petri dishes in DMEM/high glucose 
(HepG2) or low glucose (HepG2/CYP1A2)/FCS/Pen-Strep at a density of 7 x 105 cells/2 ml 
medium. After 24 h medium was replaced by fresh medium and the cells were incubated with 
the test compounds dissolved in DMSO (0.1 % final concentration) over 72 h. Negative 
controls were treated with DMSO only, 0.5 µM mitomycin C (added as solution in DMSO) 
served as positive control. Then, the cells were trypsinized and the suspensions were 
centrifugated 500 x g for 5 min. The pellet was re-suspended in 1 ml PBS plus 3 ml ice-cold 
ethanol and vortexed. After incubation at -20 °C over 30 min, the suspension was 
centrifugated at 1,000 x g for 10 min. The supernatant was discarded and the pellet was stored 
at -20°C. For micronuclei counting, the pellet was re-suspended in 750 µl DAPI dye solution 
(13.8 µg/ml aqueous DAPI solution), and vortexed. After incubation at room temperature in 
the dark over 15 min, 10 µl of the suspension were transferred to slides and covered with 
cover slips (50 x 24 mm). After adding immersion oil on the cover slip, 1,000 nuclei were 
inspected under a fluorescence microscope (Axioskop, Zeiss, Jena Germany) at 64 x 
magnification. Micronuclei were identified as round or oval-shaped bodies with a diameter of 
1/3 of the corresponding nucleus at maximum, being stained more intensively as the nucleus, 
laying adjacent to a nucleus, not showing ‘bridging’ to a nucleus, being in same optical focus 
as the corresponding nucleus. 
 
2.12. Statistical analysis and modeling 
Data represent means ± S.D. from n=3 independent experiments. For multiple comparison 
with a control, Dunnett’s test was applied with probabilities of error (p) as indicated. For 
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concentration-response modeling, threshold doses concentrations (tc) were determined using 




The synthesis of unlabeled and isotope-labeled N2-(isoestragole-3‘-yl)-2‘-desoxyguanosine 
(E3’N2dG) and N6-(isoestragole-3‘-yl)-desoxyadenosine (E3’N6dA) led to the expected 
adducts as demonstrated by mass (Figs. 1 A and B)  and 1H-NMR spectroscopy. The 
reference compounds were used as calibration standards for the quantitative analysis of both 
adducts in pRH.  
In pRH, estragole led to a slight non-significant decrease in viability (data not shown) 
whereas HepG2-CYP1A2 cells were more sensitive with a significant loss in viability at 30 
μM and above (Fig. 2). These data point to differences in handling of the substrate including 
uptake and metabolic activation and/or inactivation. The loss of viability in HepG2-CYP1A2 
cells did not exceed 50 %, a condition for the micronuclei assay (OECD, 2016). Non-
transfected HepG2 cells showed no estragole toxicity as expected due to the lack of critical 
CYP activities.  
There, incubation with increasing estragole concentrations led to a time- and concentration-
dependent increase in DNA adducts. Both adducts were found in an approximate ratio of 
dA:dG of 1:10. Significant levels of adducts were found already after 6 h at > 10 μM and after 
12 h at > 1 μM estragole. The time course of adduct levels was relatively similar between the 
dA (Fig. 3A) and dG (Fig. 3B) adduct. At estragole concentrations above 10 μM, the highest 
levels were seen after 12 h and a decrease by about 10 – 40 % after 48 h. Interestingly, the dG 
adduct level decreased more effectively over time than the dA adduct level. However, this 
time course was seen only for substrate concentrations >100 μM while at lower substrate 
concentrations levels remained almost constant or even increased between 6 and 48 h.  
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In a next step a concentration-response analysis for adduct levels was carried out to gain more 
information about the underlying mathematical function and key parameters. For this purpose, 
the data were modeled against a broken stick, which reveals a threshold concentration (tc) +/- 
95% confidence intervals. Should the intervals have bridged zero, the response was 
considered linear. Given the protracted dose concentration range, and the subsequent 
compression of the lower doses concentrations (apparent in Fig. 4A), it was considered 
judicious to model both the entire dose concentration-range and the lower doses 
concentrations alone, in case potential tcs, at the lower concentrations, were being masked by 
this compression. 
The analysis of the dA adduct revealed a linear relationship between the substrate 
concentration and the adduct level if the total concentration range was considered (Fig. 4A). 
When the calculation was focused on the three lowest estragole concentrations (< 1 μM), 
however, a non-linear function became obvious (Fig. 4B) which allowed the estimation of a 
‘practical threshold’ at a concentration of about 0.55 μM (95% confidence interval, rounded: 
0.46 - 0.99 μM). Below this concentration no increase in adduct levels above the LOQ and no 
effect of estragole on the adduct level could be observed. For the dG adduct a very similar 
picture was obtained for all concentrations (Fig. 4C) and for the lowest concentration range at 
< 1 μM (Fig. 4D). From these data a practical threshold of about 0.47 μM (95% confidence 
interval, rounded: 0.43 - 0.99 μM) could be derived. It needs to be mentioned that this type of 
influence of the concentration range was obtained for all time points analyzed, i.e. after 1, 6, 
24 and 48 h of treatment for the dG adduct and after 6, 24, and 48 h for the dA adduct (after 1 
h, no dA adducts were found at estragole concentrations < 1 μM). The calculated threshold 
concentrations were relatively independent from the time point, i.e. were at 0.5 μM as a mean 
value (Table 2).  
In order to analyze the genotoxic consequences related to estragole exposure, we next 
analyzed the levels of micronuclei in HepG2-CYP1A2 cells. Estragole concentrations 
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between 1 and 300 μM led to a concentration-dependent increase in micronuclei counts. At 
the lowest concentration of 1 μM the number was already significantly increased when 
compared to the control (Fig. 5). Testing of lower concentrations did not lead to increases 
over the control rate. However, the large variability between measurements in this 
concentration range (data not shown) did not warrant a concentration-response modeling. 
 
4. Discussion 
Estragole, a natural constituent in a variety of herbs and spices used in food and/or 
phytomedicine, has drawn much attention with respect to its hepatotoxic and carcinogenic 
properties (Martins et al., 2018). Thus, there is an increasing need for a thorough assessment 
of the risk of human estragole exposure with a special emphasis on the mode(s) of action of 
the compound and the dose (concentration) - response characteristics. Here, we investigated 
cytotoxicity and DNA adduct levels in estragole-treated rat pRH as a prototype target cell 
type for estragole toxicity. As a suitable human cell model for genotoxicity and cytotoxicity 
testing of estragole, metabolically competent HepG2-CYP1A2 cells were used.  
In previous studies, postnatal treatment of mice with estragole or 1'-hydroxyestragole 
significantly increased the incidences of hepatoma and hepatocellular carcinoma in the adult 
animals (Drinkwater et al., 1976; Miller et al., 1983). The affected livers also showed various 
types of non-neoplastic lesions such as chronic inflammation, portal fibrosis, bile duct 
proliferation, and focal areas of atypical cellular hyperplasia and megalocytosis. In rats, the 
evidence for carcinogenicity of estragole is less clear. At relatively high dose levels (75-600 
mg/kg b.w. per day), pre-neoplastic lesions such as hepatocellular hypertrophy, bile duct and 
oval cell hyperplasia, cholangiofibrosis, and chronic periportal inflammation were observed 
(NTP, 2011). Auerbach et al. (2010) reported changes in hepatic gene expression in estragole-
treated rats, indicating that estragole, also in rats, should be classified as a hepatocarcinogen.  
In our study, estragole did not exert significant cytotoxicity in pRH over an incubation period 
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of 24 h. Longer incubation periods were not used because of the substantial loss of drug-
metabolizing enzyme activities in pRH cultured over longer time (Gao et al., 2020). In 
contrast, human HepG2-CYP1A2 cells showed some cytotoxicity at estragole concentrations 
> 30 μM after 24 h incubation plus 72 h recovery, a schedule also used for the micronuclei 
assay. It has to be noted that none of the concentrations led to a loss in vitality exceeding 50 
% as recommended by the OECD as a condition for micronuclei analysis (OECD, 2016). In 
non-transformed HepG2 cells, no cytotoxicity was observed which is in agreement with the 
assumption that certain CYP activities are crucial for estragole toxicity. 
The major pathways of estragole metabolism include O-demethylation at the aromatic ring, 
epoxidation at the double bond of the allyl side chain, and 1’-hydroxylation at the allylic side-
chain with subsequent enzymatic sulfation (Smith et al., 2002). The latter pathway leads to a 
semi-stable, reactive conjugate which can undergo sulfate elimination under formation of 
covalent bonds of the remaining moiety to nucleophilic targets, mainly in the liver (Phillips et 
al., 1981). The major enzymes catalyzing the initial step (1’-hydroxylation) are cytochromes 
P450 (CYP), most notably CYP1A2 (Jeurissen et al., 2007). There is evidence that the ratios 
between the major pathways change with dose, i.e., in rodents the percentage of the 
metabolite 1’-hydroxyestragole among the total urinary radioactivity decreased with 
decreasing dose (Anthony et al., 1987). The authors discussed that this trend was likely to be 
relevant in humans where background exposure to estragole via food etc. was estimated to be 
in the range of 10 μg per kg b.w. per day (Smith et al., 2002). Likewise, Zeller et al. (2009) 
found that only a very small proportion of estragole ingested with a fennel fruit infusion by 
seven test persons appears to be metabolized to the crucial 1´-hydroxyestragole. In a human 
volunteer, the percentage of 1’-hydroxyestragole excreted via urine declined with decreasing 
estragole exposure.  
DNA adduct formation was considered as a hallmark of the liver carcinogenicity of estragole 
(Miller and Miller, 1983). In spite of its ability to covalently modify DNA bases, the 
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compound was classified based on dose-response considerations by Martins et al. (2012) as a 
‘weak’ genotoxin and carcinogen. In fact, relatively high dose levels were required to cause 
DNA adducts and mutations in rodent liver (Suzuki et al. 2012a;b). Paini et al. (2010) tried to 
predict the formation of DNA adducts in the liver of male rats on the basis of in vitro 
incubations with pRH exposed to 1’-hydroxyestragole at concentrations between 0.5 and 150 
μM. The model suggests that the formation of E3’N2dG, the principal dG-adduct in rat liver, is 
linear up to a dose of at least 100 mg estragole/kg b.w. allowing the estimation of adduct 
yields at human background exposure levels. Later, Paini et al. (2012) reported a dose-
dependent increase in the levels of E3’N2dG in the liver of estragole-treated rats being 
statistically significant at and above 30 mg/kg b.w. It has to be noted, however, that the actual 
human exposure estimates, e.g., from herbal teas (0.5 mg estragole per day) and other food 
items are at least one order of magnitude lower (Smith et al., 2002).  
Formation of the E3’N2dG adduct has been demonstrated by Young et al. (2020) in pRH 
treated for 2 h with 50 μM estragole. The authors found about 100 adducts per 108 bases, i.e., 
a much lower adduct density than in the present study. The difference is probably due to the 
much lower time of exposure compared to our study where the highest adduct numbers were 
achieved after 12 - 48 h. In our study, estragole concentrations below 1 μM did not lead to 
significant adduct levels although an LOQ of one adduct in 108 bases was achieved. At 1 and 
10 μM, a time-dependent increase in adduct levels was obtained, whereas at higher 
concentrations, a decrease was seen at later time points. This finding may be due to increased 
apoptosis and/or repair in adduct-bearing cells. The efficiency of repair of alkenylbenzene 
DNA adducts other than E3’N2dG has not been studied in detail so far (Yang et al., 2020). In 
HepaRG cells, CHO cells, and pRH, no or very limited disappearance of E3’N2dG was 
observed over several hours indicating marked persistence of the major adduct (Yang et al., 
2020)’. The authors concluded from molecular dynamics simulations that conformational 
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changes in double-stranded DNA by the E3′N2dG adduct are small, thus probably making it 
rather ineffective in triggering repair.’ 
From the data presented here, it is evident that the concentration-response characteristics for 
the levels of the two prominent estragole-derived adducts at dA and dG in pRH were linear 
when the whole concentration range between 0 and 300 μM was considered. It became 
hypolinear, however, when the modeling was focused on estragole concentrations < 1 μM. 
There, the adduct levels were not different from the untreated controls and did not increase 
significantly with increasing substrate concentrations. This effect is due to the overweight of 
data at higher concentrations resulting in a relatively good fit to the linear model. In contrast, 
hypo-linearity of dose-response functions of genotoxic carcinogens is frequently observed in 
toxicology, in particular at very high and very low dose levels (Clewell et al., 2019). Such 
findings are probably due to a number of factors (Thomas et al., 2015) such as i) the level of 
DNA adducts depends not only on their formation via a reactive intermediate but also on the 
efficacy of their repair, ii) metabolic detoxification pathways, both enzyme-catalyzed or non-
enzymatic, show a certain, limited capacity. Once being overwhelmed by increasing doses of 
a toxicant, the latter may get a chance to exert its toxicity to a full degree. It is currently not 
known if the lack of detectable adduct levels at low estragole concentrations is due to the 
aforementioned mechanisms.  
There is good evidence that estragole is genotoxic in rat hepatocytes, e.g., in the UDS assay in 
vitro (Howes et al., 1990) or ex vivo in cells isolated form estragole-treated rats (Nesslany et 
al., 2010). The doses required for a positive response in the latter study, however, were at 250 
mg/kg b.w. and above, i.e., at relatively high levels.  
Here, we investigated micronuclei formation in human HepG2 cells and in the HepG2-
CYP1A2 clone treated with estragole. Micronuclei formation was strictly dependent on the 
presence of CYP1A2. Furthermore, linear concentration-response characteristics were found 
for estragole concentrations between 1 and 300 μM. At 1 μM the micronuclei counts were still 
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statistically significantly different from the vehicle controls. Unfortunately, the relatively high 
variability in micronuclei counts, also between investigators, did not allow a reliable 
modeling of counts below 1 μM, which were not significantly, however, different from the 
vehicle control.  
DNA adduct formation is considered as an important contributor to the genotoxicity of 
estragole. Since the liver is the principal target organ of carcinogenicity in mice and probably 
also in rats and estragole leads to metabolism-related DNA adducts in the target organ, it 
fulfills the criteria for a genotoxic carcinogen. It appears plausible to regard DNA adduct 
formation and damage as key initiating events in estragole carcinogenicity. However, our data 
and data by others provide evidence that the underlying dose (concentration)-response 
relationship in target cells is hypo-linear at the lower, more relevant end of the substrate 
concentrations. Thus the default assumption of dose-linearity of carcinogenicity of estragole 
strongly based on dose-response data at high concentrations/doses is probably inadequate, at 
least based on our in vitro findings, and needs to be replaced by a thorough dose-response 
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Fig. 1. Structural formulae, masses ([M+H]+), fragmentation pattern ([M+H]+, and MS2-
spectra) of (A) N6-(isoestragole-3‘-yl)-desoxyadenosine (E3’N6dA), and (B) N2-(isoestragole-
3‘-yl)-2‘-desoxyguanosine (E3’N2dG). 
 
Fig. 2. Cytotoxicity of estragole (μM) in HepG2 cells (open bars) and HepG2-CYP1A2 cells 
(scattered bars) measured as percent resazurin reduction compared to vehicle (DMSO) only - 
treated controls. Cells were treated over 24 h and kept in culture for additional 72 before 
measurement. Bars represent means ± S.D. from n=3 independent experiments. **symbolize 
statistically significant differences from the control at p < 0.01.  
   
Fig. 3. Adduct levels (adducts per 108 nucleosides) in rat hepatocytes in primary culture 
treated with vehicle (DMSO) only (‘0’) or various concentrations of estragole, over 6, 12, 24 
or 48 h as indicated. Bars represent means ± S.D. for E3’N6dA (A) or E3’N2dG (B) from n=3 
independent experiments. Asterisks symbolize statistically significant differences from the 
control at ***p < 0.001, **p< 0.01 and *p<0.05; n.s. = non-significant. 
 
Fig. 4. ‘Broken stick’ modeling of the concentration-response relationships between estragole 
concentrations and DNA adduct levels in rat hepatocytes in primary culture after 48 h of 
incubation. Data points represent all biological (n=3) and technical (n=3-4) replicates for 
E3’N6dA (A,B) and E3’N2dG (C,D) over the estragole concentration ranges between 0 and 





Fig. 5. Micronuclei levels (micronuclei per 1,000 nuclei) in HepG2 cells (open bars) and 
HepG2-CYP1A2 cells (scattered bars) treated for 24 h with increasing concentrations of 
estragole, and a recovery phase of 72 h. Bars show means and S.D. of n=3 independent 
experiments.  **symbolize statistically significant differences from the vehicle (DMSO) only 
–treated control (C) at p < 0.01.  
 
 
 
 
 
 
 
 
 
